Moderna Stock Drops After FDA Declines Review of mRNA Flu Vaccine 
Salesforce Workforce Reduction Affects Fewer Than 1,000 Roles Amid Ongoing Restructuring 
ByteDance Advances AI Chip Development With Samsung Manufacturing Talks 
Standard Chartered Names Peter Burrill as Interim Group CFO Following Diego De Giorgi’s Exit 
Ancora Holdings Builds $200M Stake in Warner Bros Discovery, Targets Netflix Asset Sale Plan 
Amazon Explores AI Content Marketplace With Media Publishers 
Lyft Shares Slide After Weak Q1 Profit Forecast and Surprise 2025 Operating Loss 
Taiwan Says Moving 40% of Semiconductor Production to the U.S. Is Impossible 
Russia Signals Further Restrictions on Telegram Amid Ongoing Regulatory Disputes 
Samsung Electronics Sees Sustained AI-Driven Demand for Memory Chips Into Next Year 
SpaceX Pivots Toward Moon City as Musk Reframes Long-Term Space Vision 
Cloudflare Forecasts Strong Revenue Growth as AI Fuels Cloud Services Demand 
CBA Shares Surge After Record Half-Year Profit as Rate Outlook Improves 
Canadian Airlines Suspend Cuba Flights Amid Jet Fuel Shortage and U.S. Sanctions 
Innovent Biologics Shares Rally on New Eli Lilly Oncology and Immunology Deal 
Ralph Lauren Unveils Elegant Fall 2026 Women’s Collection Ahead of New York Fashion Week 
xAI Co-Founder Jimmy Ba Departs as Elon Musk’s AI Startup Faces Turbulence 
NEW YORK, Nov. 14, 2017 -- The following statement is being issued by Levi & Korsinsky, LLP:
To: All persons or entities who purchased or otherwise acquired securities of Novan, Inc. (“Novan”) (NASDAQ:NOVN) (1) pursuant and/or traceable to Novan’s IPO on or about September 26, 2016 or (2) between September 26, 2016 and January 26, 2017. You are hereby notified that a securities class action lawsuit has been commenced in the United States District Court for the Middle District of North Carolina. To get more information go to:
http://www.zlk.com/pslra-sbm/novan-inc?wire=3
or contact Joseph E. Levi, Esq. either via email at [email protected] or by telephone at (212) 363-7500, toll-free: (877) 363-5972. There is no cost or obligation to you.
The complaint alleges that the Company made materially false and/or misleading statements in its Registration Statement and Prospectus for the IPO, and made false statements throughout the class period. In particular, among other allegations, the complaint alleges that the Company repeatedly falsely stated that two Phase 3 clinical trials for the treatment SB204 were identical and omitted specific facts as to why the two critical trials were, in fact, not identical; as a result of these false statements, the Company’s outlook and expected financial performance were not accurately represented.
If you suffered a loss in Novan you have until January 2, 2018 to request that the Court appoint you as lead plaintiff. Your ability to share in any recovery doesn’t require that you serve as a lead plaintiff.
Levi & Korsinsky is a national firm with offices in New York, California, Connecticut, and Washington D.C. The firm’s attorneys have extensive expertise and experience representing investors in securities litigation, and have recovered hundreds of millions of dollars for aggrieved shareholders. Attorney advertising. Prior results do not guarantee similar outcomes.
CONTACT:
Levi & Korsinsky, LLP
Joseph E. Levi, Esq.
30 Broad Street - 24th Floor
New York, NY 10004
Tel: (212) 363-7500
Toll Free: (877) 363-5972
Fax: (212) 363-7171
www.zlk.com
